Eric Poma, Ph.D.
Chief Executive Officer & Chief Scientific Officer
Eric Poma, Ph.D. has served as Molecular Templates’ Chief Executive Officer and Chief Scientific Officer since the Company’s inception in 2009. From March 2005 until September 2008, Dr. Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems. (now Eli Lilly and Company) a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer at Molecular Templates, he led the invention of the technology underlying Molecular Templates’ platform technology and what constitutes the whole of Molecular Templates’ current lead and preclinical pipeline candidates. Dr. Poma received his Doctor of Philosophy in Microbiology and Immunology and Bachelor of Arts in Biology from the University of North Carolina at Chapel Hill and his Master of Business Administration from New York University.
President & Chief Operating Officer
Jason Kim joined Molecular Templates in 2010 and serves as President and Chief Operating Officer. He served as Molecular Templates’ President and Chief Financial Officer from February 2010 to August 2017. Previously, Mr. Kim led corporate development and strategic planning initiatives at OSI Pharmaceuticals (acquired by Astellas) and ImClone Systems (acquired by Lilly). He served as an investment professional at Domain Associates and Safeguard Scientifics where he focused on venture and public investments in biotechnology. Mr. Kim holds a Master of Business Administration from The Wharton School and a Bachelor of Arts in Neuroscience from Wesleyan University.
Roger Waltzman, M.D.
Chief Medical Officer
Roger Waltzman, M.D., M.B.A. joined Molecular Templates as Chief Medical Officer in February 2019. He is a board-certified medical oncologist whose career highlights include multiple senior drug development roles at Novartis Oncology (2007–2013), where he played a leading role in the development of imatinib, nilotinib, and ruxolitinib. From 2013 to 2016, Dr. Waltzman was the Full Development Head of Malaria Drug Development at Novartis. More recently, Dr. Waltzman was CMO at Rgenix, where he supervised the development of immuno-oncology and metabolic inhibitor assets through Phase 1 a/b. Previously, he served as CSO at Jaguar Health and Napo Pharmaceuticals, where he led scientific aspects of development and commercialization of Mytesi® (crofelemer).
Before joining the industry, Dr. Waltzman held assistant professorships in medical oncology and palliative care at Saint Vincent’s Hospital and Mount Sinai School of Medicine in New York. He completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Waltzman earned a Master of Business Administration at Columbia Business School and a Doctor of Medicine and Bachelor of Arts from Brown University.
Interim Chief Financial Officer
Senior Vice President, Finance and Corporate Controller
Sean McLennan, M.B.A. C.P.A. (inactive), joined Molecular Templates in November 2019 and serves as Senior Vice President Finance and Corporate Controller. Prior to joining Molecular Templates, Mr. McLennan was the Chief Financial Officer of Sunstar Americas, a privately held CPG company, serving in that role since 2016. Mr. McLennan has over 20 years of experience in the Life Sciences industry, working in Finance and Operational roles of increasing responsibility at Baxter International Inc. and Takeda Pharmaceutical Company Limited. He holds a Master of Business Administration from DePaul University and has a Bachelor of Arts in Finance from Illinois State University.
Senior Vice President, Project & Alliance Management
Michael Dowd joined Molecular Templates in January 2020 and serves as Senior Vice President, Project & Alliance Management. Prior to joining Molecular Templates, Mr. Dowd served in a variety of project management and alliance management positions in the biotech, pharmaceutical, and orthopedic industries, including most recently as Associate Vice President, Project & Portfolio Management, at Eli Lilly and Co. Prior to that, Mr. Dowd had roles at ImClone Systems, Innovive Pharmaceuticals, NPS Pharma, and Osteotech, Inc. He has led organizations, teams, and global partnerships to successful IND’s and BLA’s with monoclonal antibodies, antibody-drug conjugates, and DNA vaccines. Michael has a Bachelor of Science in Biomedical Engineering from Boston University.
Megan Filoon joined Molecular Templates in May 2018 as Corporate Counsel and most recently served as Vice President, Legal. During her time at Molecular Templates, Ms. Filoon has managed the day-to-day operations of the legal and human resources groups and served as corporate secretary. She has been responsible for advising the senior management team on all legal activities, including corporate governance, securities, real estate and employment matters. Prior to joining Molecular Templates, Ms. Filoon was a Corporate Associate at Blank Rome LLP from 2013 to 2018, where she represented public and private companies in mergers and acquisitions, asset sales, securities offerings, business formation and corporate governance matters. Ms. Filoon earned her Juris Doctor from Rutgers School of Law, where she was the Business Editor of the Rutgers Journal of Law and Public Policy, and received a Bachelor of Arts in History and Political Science from Boston University.
Senior Vice President and Head of Manufacturing
Ryan Hawkins joined Molecular Templates in October 2019 and serves as Senior Vice President and Head of Manufacturing. Prior to joining Molecular Templates, Mr. Hawkins served as General Manager for Catalent Biologics, a contract development and manufacturing service provider, from 2017 to 2019. From 2007 to 2017, he served in operational leadership roles of increasing responsibility for Cook Pharmica LLC, including as Chief Operating Officer from 2013 to 2017, supporting a start-up phase of asset installation, clinical development and manufacturing services to double digit site commercial biologics approvals through to a successful business divestiture (Catalent) during this span. Mr. Hawkins has held various manufacturing, supply chain and technical operations leadership roles over his 22 years in the pharmaceutical/biopharmaceutical industry, including positions at Baxter International Inc. from 2001 to 2007 and Cook Pharmaceutical Solutions from 1998 to 2001. He holds a Master of Business Administration from Indiana Wesleyan University and a Bachelor of Science in Biology from the University of Wisconsin-Milwaukee.
Joseph Phillips, Ph.D.
Senior Vice President and Head of CMC Development
Joseph Phillips, Ph.D. joined Molecular Templates in June 2020 and serves as Senior Vice President and Head of CMC Development. Before joining Molecular Templates, he was Senior Vice President and Head of Pharmaceutical Development at ArmaGen, Inc., leading CMC, manufacturing and clinical supply operations for biologic therapeutics developed for neurological disorders and neurodegenerative diseases. Prior to ArmaGen, Dr. Phillips was an independent consultant providing expertise in bioprocess and product development, manufacturability, QbD, cGMP production, technical operations, quality and global CMC submissions. Previously, he was at Amgen, Inc. serving in several leadership roles in process and product development associated with the successful implementation of platform manufacturing processes and application of single-use manufacturing technology. Before joining Amgen, Mr. Phillips worked at The Upjohn Company (Pfizer/Pharmacia) and GSK in drug substance and drug product development. Mr. Phillips received his Ph.D. in pharmaceutics and analytical chemistry from University of Brighton (UK), his M.Sc. in organometallic chemistry from University of Sussex (UK) and his B.Sc. in applied chemistry from University of Brighton (UK).
Senior Vice President, Clinical Operations
Kristen Quigley joined Molecular Templates in 2018 and serves as Senior Vice President, Clinical Operations. Previously, she led Clinical Operations teams at Threshold Pharmaceuticals, Inc., which merged with Molecular Templates in 2017, and Affymax, Inc. Ms. Quigley has worked solely in the field of oncology since 2014; prior to 2014, fifteen of her twenty-four years in the clinical research field were spent in CRO Project Management and Clinical Trial Management roles, where she successfully led Phase 1-4 study project teams in multiple indications including osteo and rheumatoid arthritis, chronic renal failure, ulcerative colitis and obesity. Ms. Quigley holds a Bachelor of Arts in Psychology from Washington University in St. Louis.